BZA 5B
Alternative Names: BZA5BLatest Information Update: 15 Mar 2007
Price :
$50 *
At a glance
- Originator Genentech
- Class Antineoplastics
- Mechanism of Action Farnesyltranstransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 15 Mar 2007 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 17 Oct 1996 Preclinical development for Cancer in USA (Unknown route)